Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

• Published in: International journal of infectious diseases Vol. 122; pp. 585 - 592
• Main Authors: Isa, Flonza, Forleo-Neto, Eduardo, Meyer, Jonathan, Zheng, Wenjun, Rasmussen, Scott, Armas, Danielle, Oshita, Masaru, Brinson, Cynthia, Folkerth, Steven, Faria, Lori, Heirman, Ingeborg, Sarkar, Neena, Musser, Bret J., Bansal, Shikha, O'Brien, Meagan P., Turner, Kenneth C., Ganguly, Samit, Mahmood, Adnan, Dupljak, Ajla, Hooper, Andrea T., Hamilton, Jennifer D., Kim, Yunji, Kowal, Bari, Soo, Yuhwen, Geba, Gregory P., Lipsich, Leah, Braunstein, Ned, Yancopoulos, George D., Weinreich, David M., Herman, Gary A.
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.09.2022; The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases; Elsevier
• Subjects: Adult; Antibodies, Monoclonal, Humanized; Casirivimab; COVID-19; COVID-19 - prevention & control; COVID-19 Drug Treatment; Double-Blind Method; Humans; Imdevimab; Monoclonal antibody; SARS-CoV-2; COVID-19; SARS-CoV-2; Imdevimab; Monoclonal antibody; Casirivimab

•Phase 1 study assessed monthly casirivimab+imdevimab (CAS+IMD) in uninfected adults•Repeat monthly CAS+IMD (1200 mg subcutaneously [SC]) was well-tolerated, with low immunogenicity•CAS+IMD (1200 mg SC) showed a substantial risk reduction in COVID-19 occurrence A phase 1, double-blind, placebo-contr...